Aripiprazole partial agonism at 5-HT2C: A comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 14, Issue 5, 2012, Pages

  Nguyen, Charles T ^a,b   Rosen, Jennifer A ^a,c,d   Bota, Robert G ^e  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN 2C ANTAGONIST; SERTRALINE; VENLAFAXINE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; BODY MASS; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DRUG RECEPTOR BINDING; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; REVIEW; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

EID: 84869486637     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.12m01386     Document Type: Review

References (38)

1. Aulakh CS, Hill JL, Yoney HT, et al. Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Psychopharmacology (Berl). 1992;109(4):444-448. PubMed doi:10.1007/BF02247721 ShowAbstract ShowAbstract
2. Garattini S, Mennini T, Samanin R. Reduction of food intake by manipulation of central serotonin: current experimental results. Br J Psychiatry suppl. 1989; (8): 41-51. PubMed ShowAbstract ShowAbstract
3. Walsh AE, Smith KA, Oldman AD, et al. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (Berl). 1994;116(1):120-122. PubMed doi:10.1007/BF02244883 ShowAbstract ShowAbstract
4. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature. 1995;374(6522):542-546. PubMed doi:10.1038/374542a0 ShowAbstract ShowAbstract
5. De Luca V, Mueller DJ, de Bartolomeis A, et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol. 2007;10(5):697-704. PubMed doi:10.1017/S1461145707007547 ShowAbstract ShowAbstract
6. Kirk SL, Glazebrook J, Grayson B, et al. Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl). 2009;207(1):119-125. PubMed doi:10.1007/s00213-009-1639-8 ShowAbstract ShowAbstract
7. Stark JA, McKie S, Davies KE, et al. 5-HT(2C) antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur J Neurosci. 2008;27(2):457-465. PubMed doi:10.1111/j.1460-9568.2007.06002.x ShowAbstract ShowAbstract
8. Wang H, Huang Z, Huang L, et al. Hypothalamic Ahi1 mediates feeding behavior through interaction with 5-HT2C receptor. JBiol Chem. 2012;287(3):2237-2246. PubMed doi:10.1074/jbc.M111.277871 ShowAbstract ShowAbstract
9. Opgen-Rhein C, Brandl EJ, Müller DJ, et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics. 2010;11(6):773-780. PubMed doi:10.2217/pgs.10.50 ShowAbstract ShowAbstract
10. Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. JClin Endocrinol Metab. 2011;96(3):837-845. PubMed doi:10.1210/jc.2010-1848 ShowAbstract ShowAbstract
11. Wang B, Chehab FF. Deletion of the serotonin 2C receptor from transgenic mice overexpressing leptin does not affect their lipodystrophy but exacerbates their diet-induced obesity. Biochem Biophys Res Commun. 2006;351(2):418-423. PubMed doi:10.1016/j.bbrc.2006.10.033 ShowAbstract ShowAbstract
12. Zhang JY, Kowal DM, Nawoschik SP, et al. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006;71(4):521-529. PubMed doi:10.1016/j.bcp.2005.11.007 ShowAbstract ShowAbstract
13. Meltzer HY. Beyond serotonin. JClin Psychiatry. May 1991;52(suppl):58-62. PubMed ShowAbstract ShowAbstract
14. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 1991;17(2):263-287. PubMed ShowAbstract ShowAbstract
15. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. JPharmacol Exp Ther. 1989;251(1):238-246. PubMed ShowAbstract ShowAbstract
16. Jann MW. Clozapine. Pharmacotherapy. 1991;11(3):179-195. PubMed ShowAbstract ShowAbstract
17. Moore NA, Rees G, Sanger G, et al. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol. 1994;5(2):196-202. PubMed doi:10.1097/00008877-199404000-00011 ShowAbstract ShowAbstract
18. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. PubMed ShowAbstract ShowAbstract
19. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1-3):103-110. PubMed doi:10.1016/j.schres.2008.09.025 ShowAbstract ShowAbstract
20. Wilson JD, Hillas JL. Astemizole: a new long-acting antihistamine in the treatment of seasonal allergic rhinitis. Clin Allergy. 1983;13(2):131-140. PubMed doi:10.1111/j.1365-2222.1983.tb02580.x ShowAbstract ShowAbstract
21. Knight A. Astemizole-a new, non-sedating antihistamine for hayfever. JOtolaryngol. 1985;14(2):85-88. PubMed ShowAbstract ShowAbstract
22. Howarth PH, Emanuel MB, Holgate ST. Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels. Br J Clin Pharmacol. 1984;18(1):1-8. PubMed ShowAbstract ShowAbstract
23. Rockwell WJ, Ellinwood EH Jr, Trader DW. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J. 1983;76(11):1407-1412. PubMed doi:10.1097/00007611-198311000-00021 ShowAbstract ShowAbstract
24. Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management. Clin Neuropharmacol. 1988;11(suppl 1):S194-S206. PubMed ShowAbstract ShowAbstract
25. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. JClin Psychiatry. 1999;60(6):358-363. PubMed doi:10.4088/JCP.v60n0602 ShowAbstract ShowAbstract
26. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169-179. PubMed doi:10.1016/j.pharmthera.2009.10.010 ShowAbstract ShowAbstract
27. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? a literature review. JClin Psychiatry. 2009;70(7):1041-1050. PubMed doi:10.4088/JCP.08r04392 ShowAbstract ShowAbstract
28. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411. PubMed doi:10.1038/sj.npp.1300203 ShowAbstract ShowAbstract
29. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10(4):317-336. PubMed doi:10.1111/j.1527-3458.2004.tb00030.x ShowAbstract ShowAbstract
30. Newcomer JW. Second-Generation (atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review. CNS Drugs. 2005;19(suppl 1):1-93. PubMed doi:10.2165/00023210-200519001-00001 ShowAbstract ShowAbstract
31. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. JPharmacol Exp Ther. 2002;302(1):381-389. PubMed doi:10.1124/jpet.102.033175 ShowAbstract ShowAbstract
32. Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12(4):655-662. PubMed doi:10.1517/eoid.12.4.655.23750 ShowAbstract ShowAbstract
33. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441(3):137-140. PubMed doi:10.1016/S0014-2999(02)01532-7 ShowAbstract ShowAbstract
34. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4):325-337. PubMed doi:10.1017/S1461145703003651 ShowAbstract ShowAbstract
35. Keck PE Jr, Calabrese JR, McQuade RD, et al; Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. JClin Psychiatry. 2006;67(4):626-637. PubMed doi:10.4088/JCP.v67n0414 ShowAbstract ShowAbstract
36. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. JClin Psychiatry. 2004;65(suppl 18):47-56. PubMed ShowAbstract ShowAbstract
37. Pigott TA, Carson WH, Saha AR, et al; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. JClin Psychiatry. 2003;64(9):1048-1056. PubMed doi:10.4088/JCP.v64n0910 ShowAbstract ShowAbstract
38. Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. JClin Psychiatry. 2008;69(12):1928-1936. PubMed doi:10.4088/JCP.v69n1211 ShowAbstract ShowAbstract